NEW YORK (GenomeWeb) – Biocartis announced today that it has signed an agreement with Immunexpress to accelerate development and commercialization of Immunexpress' Septicyte test for use on Biocartis' Idylla platform.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.